{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:42:04Z","timestamp":1777419724278,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T00:00:00Z","timestamp":1332806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Vancomycin is often the drug of choice in critically ill patients with gram-positive infections, although circumstances often prevent its use. In these situations, clinicians are frequently left with limited data regarding alternative agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe patients with reported sepsis receiving daptomycin in a critical care unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This multicenter, noncomparative, noninterventional study identified patients in critical care units, using the Cubicin Outcomes Registry and Experience (CORE) 2005-2009 registry. A descriptive account of patient characteristics, infectious etiology, outcomes at the end of daptomycin therapy, and 30-day mortality is reported. Nonevaluable patients were excluded from the efficacy analysis but included in the safety analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 128 patients, 98 (77%) of whom were evaluable for efficacy. Patient characteristics for the efficacy population were 55 (56%) males, 30 (31%) aged 66 years or older, 38 (39%) had creatinine clearance less than 30 mL\/min, and 27 (28%) were on dialysis. Common underlying diseases included acute or chronic renal failure 44 (45%), hypertension 40 (41%), and diabetes 27 (28%). Seventy-two (73%) patients were bacteremic The most common pathogens found were methicillin-resistant Staphylococcus aureus (32%), vancomycin-resistant Enterococcus faecium (21%), and coagulase-negative staphylococci (20%). Prior to daptomycin, antibiotics were used in 84 (86%) patients, most commonly vancomycin (65\/84; 77%). The median (range) initial daptomycin dose was 6 mg\/kg (3-10) and duration of 10 days (1-58). Overall success rate was 70% (31% cured; 39% improved). Twelve adverse events possibly related to daptomycin were reported in 9 of 128 (7%) patients in the safety population; 4 of these in 4 (3%) patients were serious. The mortality rate within 30 days of completing daptomycin was 42 of 128 (33%) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These data provide preliminary results on the use of daptomycin in critically ill patients with complicated conditions. Controlled studies are needed to best evaluate daptomycin use in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1q490","type":"journal-article","created":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T20:14:41Z","timestamp":1332965681000},"page":"495-502","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Daptomycin Experience in Critical Care Patients: Results from a Registry"],"prefix":"10.1177","volume":"46","author":[{"given":"Jack E","family":"Brown","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Science, State University of New York at Buffalo; Adjunct Assistant Professor of Community and Preventative Medicine, School of Medicine, University of Rochester, Buffalo, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cory","family":"Fominaya","sequence":"additional","affiliation":[{"name":"Ralph H Johnson Veterans Administration Medical Center, Charleston, SC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith J","family":"Christensen","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Health Professions, Creighton University, Omaha, NE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A","family":"McConnell","sequence":"additional","affiliation":[{"name":"Scientific Training and Operations, Cubist Pharmaceuticals, Inc., Omaha"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C","family":"Lamp","sequence":"additional","affiliation":[{"name":"Registry Research, Cubist Pharmaceuticals, Inc., Lexington, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,3,27]]},"reference":[{"key":"bibr1-aph.1Q490","first-page":"459","volume":"110","author":"Kula R","year":"2009","journal-title":"Bratisl Lek Listy"},{"key":"bibr2-aph.1Q490","first-page":"629","volume":"138","author":"Rudiger A","year":"2008","journal-title":"Swiss Med Wkly"},{"key":"bibr3-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000217961.75225.E9"},{"key":"bibr4-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.1.146"},{"key":"bibr5-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2008.02.007"},{"key":"bibr6-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.07.008"},{"key":"bibr7-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M085"},{"key":"bibr8-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1754"},{"key":"bibr9-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.02.008"},{"key":"bibr10-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1086\/591861"},{"key":"bibr11-aph.1Q490","volume-title":"Cubicin (daptomycin)","author":"Product information.","year":"2010"},{"key":"bibr12-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-009-1738-3"},{"key":"bibr13-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir078"},{"key":"bibr14-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1086\/600877"},{"key":"bibr15-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1086\/600884"},{"key":"bibr16-aph.1Q490","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01602-07"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1Q490","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1Q490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:11:40Z","timestamp":1777374700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1Q490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,27]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1345\/aph.1Q490"],"URL":"https:\/\/doi.org\/10.1345\/aph.1q490","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,27]]}}}